Raj Chovatiya, MD, PhD

Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.

In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.

Raj Chovatiya, MD, PhD, discusses how oral TYK2 inhibitor zasocitinib may affect scalp, nail, and hand psoriasis, clearance speed, and once-daily dosing.

Raj Chovatiya, MD, PhD, explains where oral TYK2 inhibitor zasocitinib may fit in psoriasis treatment after the FDA accepted its NDA under priority review.

Raj Chovatiya, MD, PhD, discusses why 2-year BE HEARD EXT data support earlier systemic therapy discussions and where unmet needs remain for HS.

Pooled 2-year BE HEARD EXT data show shorter disease duration was linked with higher stringent response rates to bimekizumab in HS.

Raj Chovatiya, MD, PhD, discusses why bimekizumab response durability in HS held steady regardless of disease duration, and what it means for care.

Pooled 2-year data show bimekizumab drove greater high-threshold HS responses in patients with shorter versus longer disease duration.

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

In this segment of his interview, Chovatiya speaks about how new consensus definitions on atopic dermatitis disease activity could impact clinical trials.

In this interview, Chovatiya highlights several key takeaways regarding the latest definitions highlighted by the International Eczema Council.

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

Ahead of ACAAI 2025, HCPLive spoke with Chovatiya on challenges in translating these promising immunologic targets into real-world clinical practice.

At ACAAI 2025, HCPLive spoke with Chovatiya on the OX40/OX40L pathway and what makes it an attractive therapeutic target over other established pathways.

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.

This interview from EADV highlights recent data from PRIME and PRIME2 on the effects of dupilumab (Dupixent) on itch and pain in prurigo nodularis.

In this EADV interview, Chovatiya highlights some of his session’s most notable takeaways regarding current treatments and new data in the atopic dermatitis space.

Discover how roflumilast foam transforms treatment for seborrheic dermatitis, showing effectiveness across diverse skin tones.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

In this report, Chovatiya highlights lebrikizumab’s evolving role in long-term atopic dermatitis management.

The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.

Full video: Experts discuss the overlap between immune-mediated inflammatory diseases in GI and dermatology, emphasizing the importance of cross-specialty care.

In the final segment of this HCPLive Special Report, experts discuss lingering unmet needs in cross-specialty care and look ahead to potential areas for improvement.

In part 2 of their HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, continue their in-depth conversation.

In this HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, discuss the connection between GI and dermatologic care.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.